ARRAY-818-302 The BEACON CRC Study (Binimetinib, Encorafenib, And Cetuximab COmbined to Treat BRAF-mutant ColoRectal Cancer):A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib +
cetuximab plus or minus binimetinib versus Investigator''s choice of either
irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose
disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study
contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib +
binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.